阿米奥达龙通过阻断器官酸化来抑制托尔样受体3介导核因子 κB信号通路
Yuka Yokota1, Keiko Takaki1, Kosuke Baba1
1Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto, 606-8585, Japan.
Biochemical and biophysical research communications
|March 26, 2024
概括
阿米奥达龙化物选择性地抑制了托尔类受体3 (TLR3) 途径,这是炎症的关键驱动因素. 这种药物通过防止细胞内器官酸化来阻断核因子kB (NF-kB) 信号传递,从而提供了潜在的治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 收费类受体 (TLR) 激素和促炎细胞因子激活核因子 κB (NF-κB) 信号,导致炎症反应.
- 选择性抑制特定的TLR介导途径对于向的抗炎疗法至关重要.
研究的目的:
- 为了确定TLR3介导的NF-κB信号通路的选择性抑制剂.
- 调查阿米奥达龙化影响TLR3信号传递的机制.
主要方法:
- 对RIKEN NPDepo化学图书馆进行选,以确定潜在的抑制剂.
- 使用用聚氨酸-聚乙酸 (Poly(I:C)) 刺激的人类静脉内皮细胞 (HUVEC) 进行抑制试验.
- 对基因表达 (ICAM-1,VCAM-1,E-selectin) 和NF-κB亚单元RelA核转位的分析.
主要成果:
- 艾米奥达龙化被确定为TLR3介导的NF-κB信号传递的选择性抑制剂.
- 阿米奥达龙抑制了由Poly (I:C) 诱导的ICAM-1表达,但不是由TNF-α,IL-1α或LPS诱导的.
- 阿米奥达龙降低了ICAM-1,VCAM-1和E-selectin的mRNA表达,并抑制了RelA核转位在Poly (I: C) 刺激的HUVEC中.
- 阿米奥达龙治疗减少了LysoTracker® Red DND-99的光,这表明干扰了细胞内器官酸化.
结论:
- 阿米奥达龙化可以选择性地抑制TLR3介导的NF-κB信号通路.
- 该机制涉及阻断细胞内器官酸化.
- 阿米奥达龙代表了TLR3介导的炎症状况的潜在治疗剂.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
988
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
988
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Electron Transport Chain: Complex I and II
13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832


